The therapeutic efficacy of ATO is attributed to its induced degradation effect of the promyelocytic leukemia–retinoic acid receptor α (PML-RARA) oncogenic fusion protein, thereby relieving the block in myeloid differentiation of leukemic cells (98). This evidence concerns the gene RARA and acute promyelocytic leukemia.